Infection in Patients Undergoing Thoracic Organ Transplantation: Epidemiology, Pathogenesis, and Clinical Management

  • S. J. Thaler
  • R. H. Rubin


Over the past several decades, remarkable progress has been made in the management of patients with advanced cardiac and lung disease - medications such as angiotensin-converting enzyme inhibitors for the management of heart failure, implantable defibrillators for the prevention of cardiac sudden death, such new antibiotics as the fluoroquinolones and imipenem in the treatment of pulmonary infection, and exercise rehabilitation programs have all increased in the quality of life for these patients. However, all of these measures represent disease palliation rather than curative therapy and, in recent years, it has become apparent that the best chance for rehabilitation for patients with advanced cardiac and pulmonary disease (as it is for patients with advanced liver and renal disease) occurs with transplantation[1].


Transplant Recipient Transplant Patient Lung Transplant Renal Transplant Recipient Cytomegalovirus Infection 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Rubin RH. Infections in the organ transplant recipient. In: Rubin RH, Young LS, editors: Clinical approach to infection in the compromised host, 3rd edn. New York: Plenum Press; 1994:629.Google Scholar
  2. 2.
    Kaye MP. Registry of the International Society for Heart and Lung Transplantation: Tenth Official Report-1993. J Heart Lung Transplant. 1993;12:541.PubMedGoogle Scholar
  3. 3.
    Cooper J. Lung transplantation. Curr Probl Surg. 1989;26:681.Google Scholar
  4. 4.
    Hofflin JM, Potasman I, Baldwin JC et al. Infectious complications in heart transplant recipients receiving cyclosporin and corticosteroids. Ann Intern Med. 1987;106:209.PubMedGoogle Scholar
  5. 5.
    Calhoon JH, Nichols L, Davis R et al. Single lung transplantation: factors in postoperative cytomegalovirus infection. J Thorac Cardiovasc Surg. 1992;103:21.PubMedGoogle Scholar
  6. 6.
    Meyers BR, Mendelson MH, Lansman S. Microbial contamination of solid-organ donor transport fluids leading to systemic infection (letter). Transplantation. 1992;53:1383.PubMedGoogle Scholar
  7. 7.
    Ciulli F, Tamm M, Dennis C et al. Donor-transmitted bacterial infection in heart-lung transplantation. Transplant Proc. 1993;25:1155.PubMedGoogle Scholar
  8. 8.
    Zenati M, Dowling RD, Dummer JS et al. Influence of the donor lung on development of early infections in lung transplant recipients. J Heart Transplant. 1990;9:502.PubMedGoogle Scholar
  9. 9.
    McGriffin DC, Galbraith AJ, McCarthy JB, Tesar PJ. Mycotic false aneurysm of the aortic suture line after heart transplantation. J Heart Lung Transplant. 1994;13:926.Google Scholar
  10. 10.
    Thomson D, Menkis A, Pflugfelder P. Mycotic aortic aneurysm after heart-lung transplantation. Transplant. 1989;47:195.Google Scholar
  11. 11.
    Dowling RD, Baladi N, Zenati M et al. Disruption of the aortic anastomosis after heart-lung transplantation. Ann Thorac Surg. 1990;49:l18.Google Scholar
  12. 12.
    Kramer MR, Marshall SE, Starnes VA et al. Infectious complications in heart-lung transplantation. Analysis of 200 episodes. Arch Intern Med. 1993;153:2010PubMedGoogle Scholar
  13. 13.
    Petri WA. Infections in heart transplant recipients. Clin Infect Dis. 1994;18:141.PubMedGoogle Scholar
  14. 14.
    Miller LW, Naftel DC, Bourge RC et al., Infection after heart transplantation: a multiinstitutional study. J Heart Lung Transplant. 1994;13:381.PubMedGoogle Scholar
  15. 15.
    Montgomery JR, Barrett FF, Williams TW. Infectious complications in cardiac transplant patients. Transplant Proc. 1973;5:1239.PubMedGoogle Scholar
  16. 16.
    Rand KH, Pollard RB, Merigan TC. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med. 1978;298:951.PubMedGoogle Scholar
  17. 17.
    Pouteil-Noble C, Ecochard R, Landrivon G et al. Cytomegalovirus infection-an etiological factor for rejection. A prospective study in 242 renal transplant recipients. Transplantation. 1993;55:851.PubMedGoogle Scholar
  18. 18.
    Rubin RH. The indirect effects of cytomegalovirus infection on the outcome of organ transplantation (editorial). J Am Med Assoc. 1989;261:3607.Google Scholar
  19. 19.
    Dauber JH, Paradis IL, Dummer JS. Infectious complications in pulmonary allograft recipients. Clin Chest Med. 1990;1:291.Google Scholar
  20. 20.
    Brooks RG, Hofflin JM, Jamieson SW et al. Infectious complications in heart-lung transplant recipients. Am J Med. 1985;79:412.PubMedGoogle Scholar
  21. 21.
    Dummer JS, Montero CG, Griffith BP et al. Infections in heart-lung transplant recipients. Transplantation. 1986;41:725.PubMedGoogle Scholar
  22. 22.
    Deusch E, End A, Grimm M et al. Early bacterial infections in lung transplant recipients. Chest. 1993;104:1412.PubMedGoogle Scholar
  23. 23.
    Dowling RD, Zenati M, Yousem SA. Donor-transmitted pneumonia in experimental lung allografts. J Thorac Cardiovasc Surg. 1992;103:767PubMedGoogle Scholar
  24. 24.
    Kramer MR, Denning DW, Marshall SE et al. Ulcerative tracheobronchitis after lung transplantation. A new form of aspergillosis. Am Rev Respir Dis. 1991;144:552.PubMedGoogle Scholar
  25. 25.
    Biggs VJ, Dummer S, Holsinger FC et al. Successful treatment of invasive bronchial aspergillosis after single-lung transplantation (letter). Clin Infect Dis. 1994;18:123.PubMedGoogle Scholar
  26. 26.
    Ramirez JC, Patterson GA, Winton TL et al. Bilateral lung transplantation for cystic flbrosis. J Thorac Cardiovasc Surg. 1992;103:287.PubMedGoogle Scholar
  27. 27.
    Shennib H, Noirclerc M, Ernst P et al. Double-lung transplantation for cystic fibrosis. Ann Thorac Surg. 1992;54:27.PubMedGoogle Scholar
  28. 28.
    Anthuber M, Kemkes BM, Kreuzer E et al. Mediastinitis and mycotic aneurysm of the aorta after orthotopic heart transplantation. Texas Heart Inst J. 1991;18:186.Google Scholar
  29. 29.
    Trento A, Dummer JS, Hardesty RL et al. Mediastinitis following heart transplantation: incidence, treatment and results. Heart Transplant. 1984;3:336.Google Scholar
  30. 30.
    Boyle E, Burdine J, Bolman RM. Successful treatment of mycoplasma mediastinitis after heart-lung transplantation. J Heart Lung Transplant. 1993;12:508.PubMedGoogle Scholar
  31. 31.
    Lowry P, Blankenship RJ, Gridley W et al. A cluster of Legionella sternal-wound infections due to postoperative topical exposure to contaminated tap water. N Engl J Med. 1991;324:109.PubMedGoogle Scholar
  32. 32.
    Sears AE, Roizman B. Herpes simplex viruses and their replication. In: Fields BN, Knipe DM, editors. Fields virology, 2nd edn. New York: Raven Press; 1990;1975.Google Scholar
  33. 33.
    Strauss SE, Cohen JI, Tosato G, Meier J. Epstein-Barr virus infections: biology, pathogenesis, and management. Ann Intern Med. 1993;118:45.Google Scholar
  34. 34.
    Andersson J, Emberg I. Management of Epstein-Barr virus infections. Am J Med. 1988;85:107.PubMedGoogle Scholar
  35. 35.
    Chang R, Lewis J, Reynolds R et al. Oropharyngeal excretion of Epstein-Barr virus by patients with lymphoproliferalive disorders and by recipients of renal homografts. Ann Intern Med. 1978;88:34.PubMedGoogle Scholar
  36. 36.
    Ho M, Jaffe R, Miller et al. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndrome after transplantation and its manifestations in children. Transplantation. 1988;45:719.PubMedGoogle Scholar
  37. 37.
    Lee E, Locker J, Nalesnik M et al. The association of Epstein-Barr virus with smooth-muscle tumors occurring after organ transplantation. N Engl J Med. 1995;332:19.PubMedGoogle Scholar
  38. 38.
    Grossi P, Revello M, Minoli L et al. Three-year experience with human cytomegalovirus infections in heart transplant recipients. J Heart Transplant. 1990;9:712.PubMedGoogle Scholar
  39. 39.
    Smyth R, Scott J, Borysiewicz L et al. Cytomegalovirus infection in heart-lung transplant recipients: risk factors, clinical associations, and response to treatment. J Infect Dis. 1991;164:1045.PubMedGoogle Scholar
  40. 40.
    Wreghitt T. Cytomegalovirus infections in heart and heart-lung transplant recipients. J Antimicrob Chemother. 1989;23:49.PubMedGoogle Scholar
  41. 41.
    Duncan A, Dummer J, Paradis I et al. Cytomegalovirus infection and survival in lung transplant recipients. J Heart Lung Transplant. 1991;10:638.PubMedGoogle Scholar
  42. 42.
    Hutter J, Scott J, Wreghitt T et al. The importance of cytomegalovirus in heart-lung transplant recipients. Chest. 1989;95:627.PubMedGoogle Scholar
  43. 43.
    Ettinger N, Bailey T, Trulock K et al. Cytomegalovirus infection and pneumonitis. Am Rev Respir Dis. 1993;147:1017.PubMedGoogle Scholar
  44. 44.
    Cooper D, Novitsky D, Schlegel V et al. Successful management of symptomatic cytomegalovirus disease with ganciclovir after heart transplantation. J Heart Lung Transplant. 1991;10:656.PubMedGoogle Scholar
  45. 45.
    Koskinen P, Nieminen M, Mattila S et al. The correlation between symptomatic CMV infection and CMV antigenemia in heart allograft recipients. Transplantation. 1993;55:547.PubMedGoogle Scholar
  46. 46.
    van der Bij W, van Dijk R, van Son W et al. Antigen test for early diagnosis of active cytomegalovirus infection in heart transplant recipients. J Heart Transplant. 1988;7:106.PubMedGoogle Scholar
  47. 47.
    Gema G, Zipeto D, Parea M et al. Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, DNAemia. J Infect Dis. 1991;164:488.Google Scholar
  48. 48.
    Schulman L, Reison D, Austin J et al. Cytomegalovirus pneumonitis after cardiac transplantation. Arch Intern Med. 1991;151:1118.PubMedGoogle Scholar
  49. 49.
    Duncan S, Cook D. Survival of ganciclovir-treated heart transplant recipients with cytomegalovirus pneumonitis. Transplantation. 1991;52:910.PubMedGoogle Scholar
  50. 50.
    Arabia F, Rosado L, Huston C et al. Incidence and recurrence of gastrointestinal eytomegalovirus infection in heart transplantation. Ann Thorac Surg. 1993;55:8.PubMedGoogle Scholar
  51. 51.
    Bramwell N, Davies R, Koshal A. Fatal gastrointestinal hemorrhage caused by cytoniegalovirus duodenitis and ulcerution after heart transplantation. J Heart Transplant. 1987;6:303.PubMedGoogle Scholar
  52. 52.
    Eseudero-Fabre A, Cummings O, Kirklin J et al. Cytomegalovirus colitis presenting as hematochezia and requiring resection. Arch Surg. 1992;127:102.Google Scholar
  53. 53.
    Millett R, Tomita T, Marshall H et al. Cytomegalovirus endomyocarditis in a transplanted heart. Arch Pathol Lab Med. 1991;115:511.PubMedGoogle Scholar
  54. 54.
    Gonwa T, Capehart J, Pilcher J et al. Cytomegalovirus myocarditis as a cause of cardiac dysfunction in a heart transplant recipient. Transplantation. 1989;47:197.PubMedGoogle Scholar
  55. 55.
    Kriett J, Smith C Hayden A et al. Lung transplantation without the use of anti-lymphocyte antibody preparations. J Heart Lung Transplant. 1993;14:915.Google Scholar
  56. 56.
    Fietze E, Prosch S, Reinke P. Cytomegalovirus infection in transplant recipients. Transplantation. 1994;58:675.PubMedGoogle Scholar
  57. 57.
    Docke W, Prosch S, Fietze E. Cytomegalovirus reactivation and tumour necrosis factor. Lancet. 1994;343:268.PubMedGoogle Scholar
  58. 58.
    Stein J, Volk H, Liebenthal C et al. Tumor necrosis factor alpha stimulates the activity of the human cytomegalovirus major and immediate early enhancer promoter in immature monocytic cells. J Gen Virol. 1993;74:2333.PubMedGoogle Scholar
  59. 59.
    Rubin R, Cosimi A, Tolkoff-Rubin N et al. Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation. 1977;24:458.PubMedGoogle Scholar
  60. 60.
    Braun W, Nankervis G. Cytomegalovirus viremia and bacteremia in renal allograft recipients. N Engl J Med. 1978;299:1318.PubMedGoogle Scholar
  61. 61.
    Chatterjee S, Fiala M, Weiner J et al. Primary cytomegalovirus and opportunistic infections: incidence in renal transplant recipients. J Am Med Assoc. 1978;240:2446.Google Scholar
  62. 62.
    Rinaldo C, Carney W, Richter B et al. Mechanisms of immunosuppression in cytomegalovirus mononucleosis. J Infect Dis. 1980;141:488.PubMedGoogle Scholar
  63. 63.
    Grattan M, Moreno-Cabral C, Startles V et al. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc. 1989;261:3561.Google Scholar
  64. 64.
    Everett J, Hershberger R, Norman D. Prolonged cytomegalovirus infection with viremia is associated with development of cardiac allograft vasculopathy. J Heart Lung Transplant. 1992;11:S133.PubMedGoogle Scholar
  65. 65.
    McDonald K, Rector T, Braunlin E. Association of coronary artery disease in cardiac transplant recipients with cytomegalovirus infection. Am J Cardiol. 1989;64:359.PubMedGoogle Scholar
  66. 66.
    Loebe M, Schuler S, Zais O et al. Role of cytomegalovirus infection in the development of coronary artery disease in the transplant heart. J Heart Transplant. 1990;9:707.PubMedGoogle Scholar
  67. 67.
    Kendall T, Wilson J, Radio S. Cytomegalovirus and other herpesviruses: do they have a role in the development of accelerated coronary arterial disease in human heart allografts? J Heart Lung Transplant. 1992;11:S14.PubMedGoogle Scholar
  68. 68.
    Normann S, Salomon D, Leelachaikul P et al. Acute vascular rejection of the coronary arteries in human heart transplantation: pathology and correlations with immunosuppression and cytomegalovirus infection. J Heart Lung Transplant. 1991;10:674.PubMedGoogle Scholar
  69. 69.
    Duncan S, Paradis I, Yousem S. Sequelae of cytomegalovirus pulmonary infections in lung allograft recipients. Am Rev Respir Dis. 1992;146:1419.PubMedGoogle Scholar
  70. 70.
    Scott J, Higenbottam T, Sharples L. Risk factors for obliterative bronchiolitis in heart-lung transplant recipients. Transplantation. 1991;51:813.PubMedGoogle Scholar
  71. 71.
    Beck S, Barrell B. Human cytomegalovirus encodes a glycoprlein homologous to MHC class-I antigens. Nature. 1988;331:269.PubMedGoogle Scholar
  72. 72.
    Barnes P, Grundy J. Down-regulation of the class 1 HLA heterodimer and B2-microglobulin on the surface of cells infected with cytomegalovirus, J Gen Virol. 1992;73:2395.PubMedGoogle Scholar
  73. 73.
    Ustinov J, Lahtinen T, Bruggemen C et al. Direct induction of class II molecules by cytomegalovirus in rat heart microvascular endothelial cells is inhibited by ganciclovir. Transplantation. 1994;58:1027.PubMedGoogle Scholar
  74. 74.
    Syndman D, Werner B, Heinze-Lacey B et at. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med. 1987;317:1049.Google Scholar
  75. 75.
    Syndman D, Werner B, Dougherty N et al. Cytomegalovirus immunoglobulin prophylaxis in liver transplantation. Ann Intern Med. 1993;19:984.Google Scholar
  76. 76.
    Merigan T, Renlund D, Keay S et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Engl J Med. 1992;326:1182.PubMedGoogle Scholar
  77. 77.
    Kelly J, Albert R, Wood D. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial eytomegalovirus antibody testing in lung transplant recipients. Transplantation. 1995;59:1144.PubMedGoogle Scholar
  78. 78.
    Bailey T, Trulock E, Ettinger N et al. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis. 1992;165:548.PubMedGoogle Scholar
  79. 79.
    Duncan S, Paradis I, Dauber J et al. Ganciclovir prophylaxis for cytomegalovirus infections in pulmonary allograft recipients. Am Rev Respir Dis. 1992;146:1213.PubMedGoogle Scholar
  80. 80.
    Havel M, Laczkovics A, Wolner E et al. Prophylactic use of hyperimmunoglobulin for cytomegalovirus infection in heart transplantation. Clin Ther. 1989;11:472.PubMedGoogle Scholar
  81. 81.
    Metselaar H, Balk A, Mochtar B et al. Cytomegalovirus seronegative heart transplant recipients. Prophylactic use of anti-CMV immunoglobulin. Chest. 1990;97:396.PubMedGoogle Scholar
  82. 82.
    Hibberd P, Tolkoff-Rubin N, Conti D et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med. 1995;123:18.PubMedGoogle Scholar
  83. 83.
    Morrison V, Dunn D, Manivel C et al. Clinical characteristics of posttransplant lymphoproliferative disorders. Am J Med. 1994;97:14.PubMedGoogle Scholar
  84. 84.
    Walker R, Marshall W, Strickler J et al. Pretransplantation assessment of the risk of lymphoproliferative disorder. Clin Infect Dis. 1995;20:1346.PubMedGoogle Scholar
  85. 85.
    Sullivan J, Medveczky P, Forman S et al. Epstein-Barr virus induced lymphoproliferation. N Engl J Med. 1984;311:1163.PubMedGoogle Scholar
  86. 86.
    Randhawa P, Yousem S, Epstein-Barr virus-associated lymphoproliferative disease in a heart-lung allograft. Transplantation. 1990;49:126.PubMedGoogle Scholar
  87. 87.
    Ho M, Miller G, Atehison W et al. Epstein-Barr virus infections and DNA hybridization studies in posttransplantation lymphoma and lymphoproliferative lesions: the role of primary infection. J Infect Dis. 1985;152:876.PubMedGoogle Scholar
  88. 88.
    Nalesnik M, Jaffe R, Starzl T et al. The pathology of posttransplant lymphoproliferalive disorders occurring in the selling of cvclosporin A-prednisone immunosuppression. Am J Pathol. 1988;133:173.PubMedGoogle Scholar
  89. 89.
    Kuo P, Dafoe D, Alfrey E et al. Posttransplant lymphoproliferative disorders and Epstein-Burr virus prophylaxis. Transplantation. 1995;59:135.PubMedGoogle Scholar
  90. 90.
    Pirsch J, Stratta R, Sollinger H et al. Treatment of severe Epstein-Burr virusinduced lymphoproliferative syndrome with ganciclovir: two cases after solid organ transplantation. Am J Med. 1989;86:241PubMedGoogle Scholar
  91. 91.
    Hanto D, Frizzera G, Gajl-Peczalska K et al. Acyclovir therapy of Epstein-Barr virus-induced posttransplant lymphoproliferative diseases. Transplant Proc. 1985;27:89.Google Scholar
  92. 92.
    Starzl T, Porter K, Iwatsuki S. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet. 1984;1:583.PubMedGoogle Scholar
  93. 93.
    Papadoulos E, Ludanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med. 1994;330:1185.Google Scholar
  94. 94.
    Seale L, Jones C, Kathpalia S et al. Prevention of herpesvirus infections in renal allograft recipients by low-dose oral acyclovir. J Am Med Assoc. 1985;254:3435.Google Scholar
  95. 95.
    Smyth R, Higenbotlam T, Scott J et al. Herpes simplex virus infection in heart lung transplant recipients. Transplantation. 1990;49:735.PubMedGoogle Scholar
  96. 96.
    Elliott W, Houghton D, Bryant R et al. Herpes simplex type 1 hepatitis in renal transplantation. Arch Intern Med. 1980;140:1656.PubMedGoogle Scholar
  97. 97.
    Goodman J. Possible transmission of herpes simplex virus by organ transplantation. Transplantation. 1989;47:609.PubMedGoogle Scholar
  98. 98.
    Kusne S, Schwartz M, Breinig M et al. Herpes simplex virus hepatitis after solid organ transplantation in adults. J Infect Dis. 1991;163:1001.PubMedGoogle Scholar
  99. 99.
    Straus S, Ostrove J, Inehauspe G et al. Varicella-zoster virus infections. Ann Intern Med. 1988;108:221.PubMedGoogle Scholar
  100. 100.
    Balfour H, Varicella zoster virus infections in immunocompromised hosts. Ann J Med. 1988;85:68.Google Scholar
  101. 101.
    Patti M, Selvaggi K, Kroboth F. Varicella hepatitis in the immunocompromised adult: a case report and review of the literature. Am J Med. 1990;88:77.PubMedGoogle Scholar
  102. 102.
    Nyerges G, Meszner Z, Gyarmati E et al. Acyclovir prevents dissemination of varicella in immunocompromised children. J Infect Dis. 1988;157:309.PubMedGoogle Scholar
  103. 103.
    Kitai I, King S, Gafni A. An economic evaluation of varicella vaccine for pediatric liver and kidney transplant recipients. Clin Infect Dis. 1993;17:441.PubMedGoogle Scholar
  104. 104.
    Oren I, Sobel J. Human herpesvirus type 6: review. Clin Infect Dis. 1992;14:741.PubMedGoogle Scholar
  105. 105.
    Ward K, Gray J. Efstathiou S. Brief report: primary human herpesvirus 6 infection in a patient following liver transplantation from a seropositive donor. J Med Virol. 1989;28:69.PubMedGoogle Scholar
  106. 106.
    Ukono T, Higashi K, Shiraki K et al. Human herpesvirus 6 infection in renal transplantation. Transplantation. 1990;49:519.Google Scholar
  107. 107.
    Merlino C, Giacchino F, Segolini G et al. Human herpesvirus-6 infection and renal transplantation. Transplantation. 1992;53:1382.PubMedGoogle Scholar
  108. 108.
    Clark D, Freeland J, Mackie P et al. Prevalence of antibody to human herpesvirus 7 by age. J Infect Dis. 1993;168:251.PubMedGoogle Scholar
  109. 109.
    Kalkov W, Rubin R, Liver disease in the organ transplant recipient: etiology, clinical impact, and management. Transplant Rev. 1991;5:200.Google Scholar
  110. 110.
    Wolf J, Perkins H, Schreider M et al. The transplanted kidney as at source of hepatitis B infection. Ann Intern Med. 1979;91:412PubMedGoogle Scholar
  111. 111.
    Lulwick L, Sywassink J, Corry R et al. The transmission of hepatitis B by renal transplantation. Clin Nephrol. 1983;19:317.Google Scholar
  112. 112.
    Gonzalez-Peralta R, Andres J, Tung F et al. Transplantation of a hepatitis B surface antigen-positive donor liver into a hepatitis B virus-negative recipient Transplantation. 1994;58:114.PubMedGoogle Scholar
  113. 113.
    Wachs M, Amend W, Aseher N et al. The risk of transmission of hepatitis B from HBsAg(-). HBcAb(+). HBlgM(-) organ donors. Transplantation. 1995;59:230.PubMedGoogle Scholar
  114. 114.
    Friedlander M, Kaspa R, Ruhinger D et al. Renal transplantation is not contraindicated in asymptomatic carriers of hepatitis B surface antigen. Am J Kidney Dis. 1989;24:204.Google Scholar
  115. 115.
    Rao K, Kasiske B, Anderson W. Variability in the morphological spectrum and clinical outcome of chronic liver disease in hepatitis B-positive and B-negative renal transplant recipients. Transplantation. 1991;51:391.PubMedGoogle Scholar
  116. 116.
    Pirson Y, Alexandre G, Strihou C. Long-term effect of HBs antigenemia on patient survival after renal transplantation. N Engl J Med. 1977;296:194.PubMedGoogle Scholar
  117. 117.
    Parfrey P, Forbes R, Hutchinson T et al. The clinical and pathological course of hepatitis B liver disease in renal transplant recipients. Transplantation. 1984;37:461.PubMedGoogle Scholar
  118. 118.
    Dusheiko G, Song E, Bowyer S et al. Natural history of hepatitis B virus infection in renal transplant recipients-a fifteen-year follow-up. Hepatology. 1983;3:330.PubMedGoogle Scholar
  119. 119.
    Degos F, Lugassy C, Degott C et al. Hepatitis B virus and hepatitis B-related viral infection in renal transplant recipients. Gastroenterology. 1988;94:151.PubMedGoogle Scholar
  120. 120.
    Nousbaum J, Pol S, Nalpas B et al. Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med. 1995;122:161.PubMedGoogle Scholar
  121. 121.
    Kohara M, Tanaka T, Tsukiyama-Kohara K et al. Hepatitis C virus genotypes I and 2 respond to interferon with different virologic kinetics. J Infect Dis. 1995;172:934.PubMedGoogle Scholar
  122. 122.
    Roth D, Zueker K, Cirocco R et al. The impact of hepatitis C virus infection on renal allograft recipients. Kidney Int. 1994;45:238.PubMedGoogle Scholar
  123. 123.
    Chan T, Wu P, Lau J et al. Clinicopathologic features of hepatitis C virus infection in renal allograft recipients. Transplantation. 1994;58:996.PubMedGoogle Scholar
  124. 124.
    Huang C, Liaw Y, Lai M et al. The clinical outcome of hepatitis C vims antibody-positive renal allograft recipients. Transplantation. 1992;53:763.PubMedGoogle Scholar
  125. 125.
    Chan T, Lok A, Cheng I et al. Chronic hepatitis C after renal transplantation. Transplantation. 1993;56:1095.PubMedGoogle Scholar
  126. 126.
    Rostaing L, Izopet J, Baron E et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation. 1995;59:1426.PubMedGoogle Scholar
  127. 127.
    Milfred S, Lake K, Anderson D et al. Practices of cardiothoracic transplant centers regarding hepatitis C-seropositive candidates and donors. Transplantation. 1994;57:568.PubMedGoogle Scholar
  128. 128.
    Periera B, Milford E, Kirkman R et al. Prevalence of hepatitis C virus RNA in organ donors positive for hepatitis C antibody and in the recipients of their organs. N Engl J Med. 1992;327:910.Google Scholar
  129. 129.
    Chan T, Lok A, Cheng I, Chan R. A prospective study of hepatitis C virus infection among renal transplant recipients. Gastroenterology, 1993;104:862.PubMedGoogle Scholar
  130. 130.
    Krick J, Reminton J. Toxoplasmosis in the adult-an overview. N Engl J Med. 1987;298:550.Google Scholar
  131. 131.
    McGregor C, Fleck D, Nagington J et al. Disseminated toxoplasmosis in cardiac transplantation. J Clin Pathol. 1984;37:74.PubMedGoogle Scholar
  132. 132.
    Wreghitt T, Hakim M, Gray J et al. Toxoplasmosis in heart and heart and lung transplant recipients. J Clin Pathol. 1989;42:194.PubMedGoogle Scholar
  133. 133.
    Luft B, Naot Y, Araujo F et al. Primary and reactivated Toxoplasma infection in patients with cardiac transplants. Ann Intern Med. 1983;99:27.PubMedGoogle Scholar
  134. 134.
    Holliman R, Johnson J, Adams S et al. Toxoplasmosis and heart transplantation. J Heart Lung transplant. 1991;10:609.Google Scholar
  135. 135.
    Orr K, Gould F, Short G et al. Outcome of Toxoplasma gondli mismatches in heart transplant recipients over a period of eight years. J Infect. 1994;29:249.PubMedGoogle Scholar
  136. 136.
    Araujo F, Lin T, Remington J. The activity of atovaquine (566C80) in murine toxoplasmosis is markedly augmented when used in combination with pyrimethamine or sulfadiazine. J Infect Dis. 1993;167:494.PubMedGoogle Scholar
  137. 137.
    Gryzan S, Paradis I, Zeevi A et al. Unexpectedly high incidence of Pneumocystis carinii infection after lung-heart transplantation. Am Rev Respir Dis. 1988;137:1268.PubMedGoogle Scholar
  138. 138.
    Olsen S, Renlund D, O’Connell J. Prevention of Pneutmocystis carinii pneumonia in cardiac transplant recipients by trimethoprim sulfamethoxazole. Transplantation. 1993;56:359.PubMedGoogle Scholar
  139. 139.
    Kramer M, Stoehr C, Lewiston N et al. Trimethoprim-sulfamethoxazole prophylaxis for Pneumocystis carinii infections in heart-lung and lung transplantation-how effective and for how long? Transplantation. 1992;53:586.PubMedGoogle Scholar
  140. 140.
    Keogh A, Macdonald P, Richens D et al. Mini-dose trimethoprim with sulphamethoxazole prevents pneumocystis and toxoplasmosis infections after heart transplantation. Transplant Proc. 1992;24:2263.PubMedGoogle Scholar
  141. 141.
    Lichtenslein L, MacGregor R, Mycobacterial infections in renal transplant recipients: report of live eases and review of the literature. Rev Infect Dis. 1983;5:216.Google Scholar
  142. 142.
    Maihotra K, Dash S, Dhawan I et al. Tuberculosis and renal infections-observations from an endemic area of tuberculosis. Postgrad Med J. 1986;62:359.Google Scholar
  143. 143.
    Coutts I, Jegurajah S, Stark J. Tuberculosis in renal transplant recipients. Br J Dis Chest. 1979;73:141.PubMedGoogle Scholar
  144. 144.
    Lloveras J, Peterson P, Simmons R et al. Mycohactenal infections in renal transplant recipients. Arch Intern Med. 1982;142:888.PubMedGoogle Scholar
  145. 145.
    Qunibi W, Al-Sibai B, Taher S et al. Mycobacterial infection after renal transplantation-report of 14 cases and review of the literature. Q J Med. 1990;282:1039.Google Scholar
  146. 146.
    Munoz P, Palomo J, Munoz R et al. Tuberculosis in heart transplant recipients. Clin Infect Dis. 1995;21:398.PubMedGoogle Scholar
  147. 147.
    Dromer C, Nashef S, Velly J et al. Tuberculosis in transplanted lungs. J Heart Lung Transplant. 1993;12:924.PubMedGoogle Scholar
  148. 148.
    Carlsen S, Bergin C. Reactivation of tuberculosis in a donor lung after transplantation. Am J Rocntgenol. 1990;154:495.Google Scholar
  149. 149.
    Peters T, Reiter C, Boswell R. Transmission of tuberculosis by kidney transplantation. Transplantation. 1984;38:514.PubMedGoogle Scholar
  150. 150.
    Spence R, Dafoe D, Rabin G et al. Mycobacterial infections in renal allograft recipients. Arch Surg. 1983;118:356.PubMedGoogle Scholar
  151. 151.
    Palel R, Roberts G, Keating M et al. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis. 1994;19:263.Google Scholar
  152. 152.
    Novick R, Moreno-Cabral C, Stinson K et al. Nontuberculous mycobaeteria infections in heart transplant recipients: a seventeen-year experience. J Heart Transplant. 1990;9:357.PubMedGoogle Scholar
  153. 153.
    Tebas P, Sultan F, Wallace R. Rapid development of resistance to clarithromycin following monotherapy for disseminated Microbacterium chelomae infection in a heart transplant patient. Clin Infect Dis. 1995;20:443.PubMedGoogle Scholar
  154. 154.
    Trulock E, Bolman R, Genton R. Pulmonary disease caused by Microbacterium chelonae in a heart-lung transplant recipient with obliterative bronchiolitis. Am Rev Respir Dis. 1989;140:802.PubMedGoogle Scholar
  155. 155.
    Paya C. Fungal infections in solid-organ transplantation. Clin Infect Dis. 1993;16:677.PubMedGoogle Scholar
  156. 156.
    Hibberd P, Rubin R, Clinical aspects of fungal infection in organ transplant recipients. Clin Infect Dis. 1994;19:S33.PubMedGoogle Scholar
  157. 157.
    Hall K, Copeland J, Zukoski C et al. Markers of coccidioidomycosis before cardiac or renal transplantation and the risks of recurrent infection. Transplantation. 1993;55:1422.PubMedGoogle Scholar
  158. 158.
    Meyer R, Hanberg F, Inman M et al. An orthotopic heart transplant recipient with subacute meningitis. Rev Infect Dis. 1991;13:513.PubMedGoogle Scholar
  159. 159.
    Wong S, Allen D. Transmission of disseminated histoplsmosis via cadaveric renal transplantation: case report. Clin Infect Dis. 1992;14:232.PubMedGoogle Scholar
  160. 160.
    Goodwin R, Shapiro J, Thurman G et al. Disseminated hisloplasniosis: clinical and pathologic correlations. Medicine. 1980;59:1.PubMedGoogle Scholar
  161. 161.
    Clarke A, Skelton J, Fraser R. Fungal tracheobronehitis. Medicine. 1991;7:1.Google Scholar
  162. 162.
    Mayer J, Nimer L, Carroll K. Isolated pulmonary aspergillar infection in cardiac transplant recipients: case report and review. Clin Infect Dis. 1992;15;698.PubMedGoogle Scholar
  163. 163.
    Gurwith M, Stinson E, Remington J. Aspergillus infection complicating cardiac transplantation. Arch Intern Med. 1971;128:541.PubMedGoogle Scholar
  164. 164.
    Cheung T, Simard D. Systemic Aspergillus infection: report of a fatal case nine months after renal homogratt transplantation. Br J Urol. 1971;43:174.PubMedGoogle Scholar
  165. 165.
    Byl B, Jacobs F, Antoine M et al. Mediastinitis caused by Aspergillus fumigatus with ruptured aortic pseudoaneurysm in a heart transplant recipient: case study. Heart Lung. 1993;22:145.PubMedGoogle Scholar
  166. 166.
    Duband F, Bernaul J, Dupont B et al. Aspergillus intraabdominal abscess after liver transplantation successfully treated with ilraconazole. Transplantation. 1992;54:734.Google Scholar
  167. 167.
    Lona K, Salinger M, Frohhch T et al. Primary cutaneous aspergillosis in a heart transplant recipient treated with surgical excision and oral itraconazole. J Heart Hung Transplant. 1992;11:156.Google Scholar
  168. 168.
    Gustafson T, Schaffner W, Lavely G et al. Invasive aspergillosis in renal transplant recipients: correlation with eorrticosteroid therapy. J Infect Dis. 1983;148:230.PubMedGoogle Scholar
  169. 169.
    Hall W, Martinez A, Dummer J et al. Central nervous system infections in heart and heart-lung transplant recipients. Arch Neurol. 1989;46:173.PubMedGoogle Scholar
  170. 170.
    Britt R, Enzmann D, Remington J. Intracranial infection in cardiac transplant recipients. Ann Neurol. 1981;9:107.PubMedGoogle Scholar
  171. 171.
    Treger T, Visscher D, Bartlett M, Smith J. Diagnosis of pulmonary infection caused by Aspergillus: usefulness of respiratory cultures. J Infect Dis. 1985;152:572.PubMedGoogle Scholar
  172. 172.
    Yu V, Muder R, Poorsattar A. Significance of isolation of Aspergillus from the respiratory tract in diagnosis of invasive pulmonary aspergillosis. Results from a three-year study. Am J Med. 1986;81:249.PubMedGoogle Scholar
  173. 173.
    Kusne S, Torre-Cisneros J, Manez R et al. Factors associated with invasive lung aspergillosis and the significance of positive Aspergillus culture after liver transplantation. J Infect Dis. 1992;166:1379.PubMedGoogle Scholar
  174. 174.
    John G, Mathew M, Snehalatha E et al. Cryptococcosis in renal allograft recipients. Transplantation. 1994;58:855.PubMedGoogle Scholar
  175. 175.
    Sax P, Mattia A. Case records of the Massachusetts General Hospital. Case 7-1994. N Hngl J Med. 1994;330:490.Google Scholar
  176. 176.
    Rozenbaum R, Goncalves A. Clinical epidemiological study of 171 cases of cryptococcosis. Clin Infect Dis. 1994;18:369.PubMedGoogle Scholar
  177. 177.
    Powderly W, Cloud G, Dismukes W, Saag M. Measurement of cryptococcal antigen in serum and cerebrospinal fluid: value in the management of AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1994;18:789.PubMedGoogle Scholar
  178. 178.
    Diamond R, Bennett J. Prognostic factors in eryptococcal meningitis: a study in 111 cases. Ann Intern Med. 1974;80:176PubMedGoogle Scholar

Copyright information

© Kluwer Academic Publishers 1996

Authors and Affiliations

  • S. J. Thaler
  • R. H. Rubin

There are no affiliations available

Personalised recommendations